Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Trimmed by Virtu Financial LLC

Virtu Financial LLC lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 38.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,465 shares of the medical equipment provider’s stock after selling 9,091 shares during the period. Virtu Financial LLC’s holdings in Zimmer Biomet were worth $1,561,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. American Century Companies Inc. increased its stake in Zimmer Biomet by 12.6% in the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Equity Investment Corp acquired a new position in shares of Zimmer Biomet in the third quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC increased its position in shares of Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after acquiring an additional 577,320 shares in the last quarter. Magnetar Financial LLC raised its holdings in shares of Zimmer Biomet by 58.7% during the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock valued at $142,203,000 after acquiring an additional 484,816 shares during the period. Finally, Van ECK Associates Corp lifted its position in shares of Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of several research analyst reports. BTIG Research lowered their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Raymond James reduced their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. JPMorgan Chase & Co. lowered their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, September 16th. Finally, Truist Financial increased their price target on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $122.83.

Zimmer Biomet Trading Down 0.1 %

Shares of NYSE:ZBH opened at $106.84 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $21.27 billion, a PE ratio of 20.31, a P/E/G ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90. The firm has a fifty day moving average price of $107.59 and a 200 day moving average price of $108.83.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company posted $1.65 EPS. The firm’s revenue was up 4.1% on a year-over-year basis. Analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.